Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Daniel-Dumitru Nisulescu has a total of 76 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Biatrial Inflammatory and Fibrotic Remodeling in Severe Aortic Stenosis Compared with CABG Controls

    by Adrian-Grigore Merce, Daniel Dumitru NișUlescu, Anca Hermenean, Adrian-Petru Merce, Raluca Muntean, Daniel-Miron Brie, Oana-Maria Burciu, Dan Găiță, Adina Ionac, Simina CrișAn, et al.

    Background: Extensive prior work has established severe aortic stenosis as a whole-heart remodeling process involving chronic pressure overload, concentric hypertrophy, myocardial stiffness, and progressive ventricular fibrosis. However, direct paired histological characterization of both atria remains limited. Methods: This single-center observational comparative study included 28 patients with severe aortic stenosis referred for surgical aortic valve replacement and 14 coronary artery bypass grafting (CABG) controls without significant valvular disease, consecutively enrolled between 9 May 2024 and 28 April 2025. Left- and right-atrial tissue samples were collected intraoperatively. The relative expression of interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-alpha), and transforming growth factor-beta (TGF-beta) was quantified by RT-qPCR using pooled tissue samples and interpreted descriptively as a group-level molecular output. Atrial fibrosis was measured histologically at the patient level using Masson’s trichrome staining and digital image analysis. Results: Compared with CABG controls, patients with severe aortic stenosis demonstrated greater left-atrial fibrosis (median: 19.12% [IQR: 16.12–23.12] vs. 11.54% [9.53–14.29]; p < 0.0001) and right-atrial fibrosis (16.33% [15.07–19.13] vs. 8.40% [5.75–11.27]; p = 0.0001). Pooled RT-qPCR outputs descriptively suggested higher IL-6, TNF-alpha, and TGF-beta expression in both atria, although biological replication was insufficient for inferential testing. Echocardiographically, the aortic stenosis group showed higher aortic jet velocity and transvalvular gradients, thicker ventricular walls, a larger right-ventricular diameter, higher pulmonary artery systolic pressure, and a larger estimated left-atrial volume. A sensitivity analysis of 13 within-group correlations found that no correlation retained statistical significance at q < 0.05. Exploratory regressions restricted to patient-level histological outcomes suggested that severe aortic stenosis status remained associated with left- and right-atrial fibrosis after limited adjustment for age and sex. Conclusions: These findings complement the extensive ventricular fibrosis literature by providing paired human biatrial tissue evidence of greater atrial fibrosis in severe aortic stenosis compared with CABG controls. The pooled molecular findings remain descriptive and require validation using patient-level biological measurements.


  • Open Access

    Real-World Attainment of Guideline-Recommended Lipid Targets in Patients with High and Very High Cardiovascular Risk: A Prospective 12-Month Observational Cohort Study

    by Gabriela Otiman, Ciprian Ilie Rosca, Daniel Dumitru Nisulescu, Abdeldayem Mahmoud, Ana-Maria Pah, Dana Emilia Velimrovici, Cristina Ples, Gheorghe Stoicescu-Hogea

    Background/Objectives: European guidelines recommend increasingly stringent, risk-stratified low-density lipoprotein cholesterol (LDL-C) targets, but real-world attainment remains suboptimal. We evaluated 12-month lipid-target attainment and changes in model-derived cardiovascular risk estimates in an ambulatory dyslipidaemia cohort. Methods: In this prospective, single-centre observational study, 101 consecutive adults were assessed at baseline and after at least 12 months of routine-care lipid-lowering therapy. Patients were classified as moderate/low, high, or very high cardiovascular risk. The primary endpoint was attainment of the risk-specific LDL-C target at 12 months versus baseline. Paired changes were tested using the McNemar exact and Wilcoxon signed-rank tests. Multivariable logistic regression assessed correlates of target attainment, with Firth penalisation used because of sparse outcomes in the higher risk strata. Results: LDL-C target attainment increased from 6.0% to 43.0%, and non-HDL-C attainment from 7.0% to 51.5% (both p < 0.001). At 12 months, 89% of moderate/low-risk patients reached the LDL-C target, compared with 9% of high-risk and 23% of very-high-risk patients (p < 0.001). Higher risk category was strongly associated with non-attainment, although the odds ratios were imprecise because of sparse events. Only one patient received a high-intensity statin and three received a PCSK9 inhibitor, despite 63% of the cohort being at high or very high risk. Model-derived risk scores decreased, partly as a mathematical consequence of updated lipid inputs. Therapy was well tolerated. Conclusions: Lipid control improved substantially, but target attainment remained poorest in patients at greatest cardiovascular risk. Earlier treatment intensification, structured adherence assessment, and more consistent use of combination therapy may reduce this implementation gap.

  • Open Access

    Biatrial Inflammatory and Profibrotic Remodeling in Severe Mitral Regurgitation: A Comparative Tissue and Echocardiographic Study Versus CABG Comparator Group

    by Adrian-Grigore Merce, Daniel-Dumitru NișUlescu, Anca Hermenean, Oana-Maria Burciu, Iulia-Raluca Munteanu, Adrian-Petru Merce, Daniel-Miron Brie, Anikó Mornoș, Dragoș Constantin Cozma, Raluca Coifan, et al.

    Background/Objectives: Severe mitral regurgitation (MR) is associated with chronic atrial stretch, chamber enlargement, pulmonary pressure elevation, and atrial fibrosis, yet the relationship between tissue inflammatory/profibrotic signaling, histologically quantified fibrosis, and echocardiographic remodeling remains incompletely characterized. This study aimed to compare biatrial tissue remodeling in patients with severe MR undergoing mitral valve surgery with a practical non-valvular surgical comparator group undergoing isolated coronary artery bypass grafting (CABG). Methods: This single-center, observational, cross-sectional comparative study included 36 elective cardiac-surgery patients: 22 with severe MR and 14 undergoing isolated CABG without significant valvular disease. Left- and right-atrial tissue samples were collected intraoperatively. IL-6, TNF-α, and TGF-β expression was assessed by quantitative real-time PCR using pooled atrial samples stratified by atrial side and study group, whereas atrial fibrosis was quantified histologically on individual tissue specimens using Masson’s trichrome staining and digital image analysis. Clinical, laboratory, and echocardiographic parameters were compared between groups, and exploratory associations were assessed with cautious interpretation. Results: Compared with the CABG comparator group, patients with severe MR showed a pooled molecular profile compatible with higher aggregate atrial expression of IL-6, TNF-α, and TGF-β; because qPCR was performed on pooled tissue preparations, these molecular findings were interpreted descriptively and were not used for patient-level inferential statistics. Histologically quantified fibrosis was significantly increased in severe MR in both the left atrium (29.69 ± 12.26% vs. 12.17 ± 4.56%, p < 0.0001) and the right atrium (25.25 ± 11.33% vs. 9.01 ± 4.46%, p < 0.0001). The MR group also showed more pronounced echocardiographic remodeling, including larger estimated left atrial volume, higher pulmonary artery systolic pressure, and greater right ventricular diameter. Exploratory individual-level analyses were restricted to histological fibrosis and echocardiographic variables. Conclusions: Severe MR was associated with marked echocardiographic remodeling and significantly greater histologically quantified biatrial fibrosis compared with a CABG surgical comparator group. Pooled qPCR findings support an aggregate inflammatory/profibrotic signal, but they should be interpreted descriptively because individual-level molecular variability could not be assessed. These findings are hypothesis-generating and do not establish causality.

  • Open Access

    Triglyceride–Glucose Index and Ischemic Stroke Burden in Permanent Versus Paroxysmal Atrial Fibrillation: A Real-World Retrospective Cohort Study

    by Horia Silviu Branea, Ciprian Ilie Rosca, Daniel Florin Lighezan, Violeta Ariana Nicoras, Adrian Sebastian Zus, Romina Georgiana Bita, Daniel-Dumitru Nisulescu

    Background: Atrial fibrillation (AF) is a major substrate for ischemic stroke, but cerebrovascular risk is heterogeneous and influenced by AF phenotype, comorbidities, anticoagulant exposure, renal function, and metabolic risk. The triglyceride–glucose index (TyG index) is a simple surrogate marker of insulin resistance calculated from fasting triglycerides and fasting plasma glucose. Whether the TyG index is associated with ischemic stroke burden and recurrent cerebrovascular events in patients with different AF phenotypes remains insufficiently characterized. Objective: This study aimed to evaluate the association between the TyG index and ischemic stroke burden in patients with paroxysmal and permanent AF, with particular focus on recurrent ischemic stroke. Methods: We performed a retrospective observational analysis of patients with AF divided according to AF phenotype: paroxysmal AF and permanent AF. Clinical, biological, therapeutic, and cerebrovascular variables were extracted from an existing real-world clinical database. The TyG index was calculated as ln [fasting triglycerides (mg/dL) × fasting plasma glucose (mg/dL)/2]. Triglycerides and fasting plasma glucose were measured during hospitalization; therefore, the analysis was framed as a retrospective cross-sectional association with recorded ischemic stroke burden, not as a prospective prediction study. The main outcome was any ischemic stroke. Secondary outcomes included recurrent ischemic stroke, defined as ≥2 recorded ischemic stroke events, and stroke burden categorized as no stroke, single stroke, or recurrent stroke. Continuous variables were reported as mean ± standard deviation and compared using independent samples t-tests or one-way analysis of variance, as appropriate. Results: After patient-level de-duplication, 1031 unique patients with AF were identified: 310 with paroxysmal AF and 721 with permanent AF. The strict TyG-eligible analytical cohort included 941 patients: 295 with paroxysmal AF and 646 with permanent AF. Permanent AF was associated with a higher ischemic stroke burden than paroxysmal AF. Any ischemic stroke was recorded in 325/646 patients with permanent AF compared with 79/295 patients with paroxysmal AF (50.3% vs. 26.8%, p < 0.001). Recurrent ischemic stroke was also more frequent in permanent AF (7.7% vs. 4.1%, p = 0.035). Among stroke-positive patients, the proportion with recurrent stroke was similar between permanent and paroxysmal AF (15.4% vs. 15.2%, p = 0.966). The TyG index was significantly higher in paroxysmal AF than in permanent AF (8.93 ± 0.69 vs. 8.73 ± 0.61, p < 0.001), but it did not differ significantly across stroke burden categories. In logistic regression, the TyG index was not associated with any ischemic stroke or recurrent ischemic stroke in unadjusted, age/sex-adjusted, AF phenotype-adjusted, or clinically adjusted models. Conclusions: In this real-world retrospective cohort, permanent AF was associated with a substantially higher ischemic stroke burden than paroxysmal AF. However, the TyG index was not independently associated with ischemic stroke occurrence or recurrence. Although patients with paroxysmal AF had a more adverse lipid metabolic profile and higher TyG index values, this did not translate into a higher TyG-related cerebrovascular burden. These findings suggest that the TyG index alone has limited utility as a marker of ischemic stroke burden in heterogeneous AF cohorts and that its prognostic value may depend on cardiometabolic phenotype, adiposity distribution, AF substrate, anticoagulant exposure, and the clinical context in which it is applied.

  • Open Access

    Chronic Low-Grade Inflammation: A Possible Link Between COVID-19 and New-Onset Atrial Fibrillation

    by Ciprian Ilie RoșCa, Daniel Florin Lighezan, Daniel-Dumitru NișUlescu, Nilima Rajpal Kundnani, Romina Georgiana Bita, Ariana Violeta Nicoras, Christian Banciu, Andreea Munteanu

    Background: Persistent inflammation and endothelial dysfunction have been proposed as key mechanisms of post-COVID cardiovascular sequelae and may contribute to atrial fibrillation (AF). We examined whether inflammatory/prothrombotic biomarkers and endothelial function differ between post-COVID patients and controls, and whether baseline inflammation/endothelial dysfunction relates to AF burden at 12 months. Methods: In this single-center, retrospective observational study, 198 outpatients were enrolled: 99 post-COVID patients evaluated 3–6 months after documented SARS-CoV-2 infection (Group 1) and 99 age- and sex-matched controls without prior COVID-19 (Group 2). At baseline (t0), clinical characteristics, inflammatory/prothrombotic biomarkers, brachial artery flow-mediated dilation (FMD), and 24 h Holter ECG were assessed in both groups. Univariable linear regression tested associations between baseline variables and FMD in Group 1. At 12 months (t1), 24 h Holter ECG was repeated in both groups. Quartile analyses were performed according to baseline neutrophil-to-lymphocyte ratio (NLR) to explore AF distribution across inflammatory strata. Results: At baseline, post-COVID patients had higher inflammatory and prothrombotic markers than controls (ESR, CRP, fibrinogen, and D-dimer; all p < 0.0001) and markedly lower FMD (7.72 vs. 13.72; p < 0.0001). In Group 1, FMD was inversely associated with multiple inflammatory/prothrombotic markers (all p < 0.0001), with the strongest association for ESR (R2 = 0.6297). Holter-detected AF prevalence at baseline did not differ significantly between groups (25/99 [25.3%] vs. 18/99 [18.2%]). At 12 months, AF prevalence was numerically higher in the post-COVID group (32/99 [32.3%] vs. 21/99 [21.2%]); on two-sided testing, this difference was borderline (p = 0.047) and should be interpreted cautiously. Across increasing baseline NLR quartiles, AF prevalence increased stepwise in both groups (post-COVID: 2/25, 5/25, 10/24, 15/25; controls: 1/25, 3/25, 7/24, 10/25), consistent with the enrichment of AF in higher-inflammatory strata. Conclusions: Post-COVID patients exhibited a persistent inflammatory–prothrombotic profile and pronounced endothelial dysfunction at baseline. At 12 months, AF burden was numerically higher post-COVID, and AF clustered in strata characterized by higher baseline NLR and lower FMD, consistent with an inflammation–endothelial dysfunction axis associated with subsequent AF burden. Prospective studies with standardized rhythm monitoring and comprehensive multivariable adjustment are warranted.

  • Open Access

    Triglyceride-to-HDL Cholesterol Ratio Is Associated with Ischemic Stroke Risk in Patients—With Paroxysmal Atrial Fibrillation

    by Ciprian Ilie Rosca, Daniel Florin Lighezan, Doina Georgescu, Horia Silviu Branea, Nilima Rajpal Kundnani, Ariana Violeta Nicoras, Romina Georgiana Bita, Daniel Dumitru Nisulescu

    Background: Ischemic stroke remains the most feared complication of atrial fibrillation (AF), and thromboembolic risk is commonly estimated using clinical scores that may not fully capture the cardiometabolic dimension of cerebrovascular vulnerability. The aim of this research was to assess whether additional parameters can be used, to predict ischemic stroke risk in patients with AF, in order to explore whether TG/HDL-C may complement conventional clinical risk scores for ischemic stroke risk stratification in PAF, and to better characterize a metabolically high-risk phenotype beyond the recommendations provided by the CHA2DS2-VA score, which is useful but still far from perfect in predicting AF-associated ischemic stroke risk. Methods: In this retrospective, single-center observational study, we evaluated whether the triglyceride-to-high-density lipoprotein cholesterol ratio (TG/HDLc), a simple surrogate of atherogenic dyslipidemia and insulin resistance, is associated with ischemic stroke risk in patients with paroxysmal atrial fibrillation (PAF). We screened 1111 consecutive AF admissions between 1 January 2015 and 31 December 2016 and, from these 1111 AF cases, we extracted only the patients with PAF for analysis. Patients were stratified based on TG/HDLc values into two groups, Group 1 (TG/HDLc > 2.5; n = 155) and Group 2 (TG/HDLc < 2.5; n = 194). Statistical analysis was performed with MedCalc v23.4.0 using Chi-square and unpaired/Welch’s t-tests as appropriate, Pearson correlations, Kaplan–Meier analysis with log-rank testing, Cox regression for first ischemic stroke, and multivariable logistic regression to identify independent correlates of TG/HDLc > 2.5. Results: Patients with TG/HDLc > 2.5 had a significantly higher prevalence of ischemic stroke after AF onset compared with those with TG/HDLc < 2.5 (37.4% vs. 21.1%, p = 0.0008), despite similar CHA2DS2-VA and HAS-BLED scores, and also exhibited a higher burden of cerebrovascular and neurodegenerative findings, including cortical atrophy and cerebral lacunarism. Ischemic stroke-free survival curves diverged significantly over time (log-rank p = 0.0186), and an elevated TG/HDLc ratio was associated with a 68% higher hazard of first ischemic stroke (HR 1.68; 95% CI 1.09–2.60). In multivariable analysis, type 2 diabetes mellitus (OR 4.53), hyperuricemia (OR 3.83), dyslipidemia (OR 1.94), stroke (OR 1.77), and cortical atrophy (OR 4.48) were independently associated with TG/HDLc > 2.5. Conclusions: These findings suggest that TG/HDLc identifies a metabolically high-risk PAF phenotype associated with greater cerebrovascular burden and reduced ischemic stroke-free survival, providing an inexpensive and broadly available marker that may complement conventional clinical risk scores.


  • Top Cited Papers
    Open Access

    From Metabolic Syndrome to Atrial Fibrillation: Linking Inflammatory and Fibrotic Biomarkers with Atrial Remodeling and Imaging-Based Evaluation—A Narrative Review

    by Adrian-Grigore Merce, Daniel-Dumitru Nisulescu, Anca Hermenean, Oana-Maria Burciu, Iulia-Raluca Munteanu, Adrian-Petru Merce, Daniel-Miron Brie, Cristian Mornos

    Atrial fibrillation (AF) is the most prevalent sustained arrhythmia worldwide and is now increasingly regarded as a disease of chronic inflammation and progressive atrial fibrosis. Understanding of molecular mechanisms that mediate the linkage between systemic metabolic dysregulation, inflammation, and structural atrial changes is crucial for informing risk stratification and targeting of prevention strategies. This review provides evidence from 105 studies focusing on the contributions of transforming growth factor-β1 (TGF-β1), tumor necrosis factor-a (TNF-α), interleukin-6 (IL-6), galectin-3, and galectin-1 to cardiac fibrogenesis, atrial fibrosis, and AF pathogenesis. We also link metabolic syndrome to these biomarkers and to atrial remodeling, as well as echocardiographic correlates of fibrosis. TGF-β1 is established as the central profibrotic cytokine and promotes Smad-based fibroblast activation, collagen accumulation, and structural atrial remodeling. Its role is highly potentiated by thrombospondin-1 by turning latent TGF-β1 into its potent form. TNF-α and IL-6 also play an integral role in the inflammatory fibrotic continuum by activating NF-κB and STAT3 signaling, promoting fibroblast proliferation, electrical uncoupling, and extracellular matrix accumulation. Galectin-3 is a potent profibrotic mediator that promotes TGF-β signaling and is a risk factor for negative outcomes, whereas Gal-1 seems to regulate inflammation resolution and may exert context-dependent protective or maladaptive roles. Metabolic syndrome is strongly associated with excessive levels of these biomarkers, chronic low-grade inflammation, oxidative stress, and ventricular and atrial fibrosis. Chronic clinical findings show that metabolic syndrome (MetS) increases AF risk, exacerbates atrial dilatation, and is associated with worse postoperative outcomes. Echocardiographic data are connected to circulating biomarkers and are non-invasive for evaluating atrial remodeling. The evidence to date supports that atrial fibrosis should be considered an end point of systemic inflammation, metabolic dysfunction, and activation of profibrotic molecular pathways. Metabolic syndrome, due to its chronic low-grade inflammatory environment and prolonged levels of metabolic stress, manifests as an important upstream factor of fibrotic remodeling, which continuously promotes the release of cytokines, oxidative stress, and fibroblast activation. Circulating fibrotic biomarkers, in comparison with metabolic syndrome, serve separate yet interdependent pathways that help orchestrate atrial structural remodeling through the simultaneous process but can also provide a long-term indirect measure of ongoing profibrotic activity. The integration of these biomarkers with superior atrial imaging enables a broader understanding of the fibrotic substrate of atrial fibrillation. This combined molecular imaging approach can facilitate risk stratification, refine therapeutic decisions, and facilitate early identification of higher-risk metabolic phenotypes, thus potentially facilitating directed antifibrotic and anti-inflammatory therapy in atrial fibrillation.


  • Open Access

    Clinical Significance of TAPSE/PASP Ratio in Risk Stratification for Aortic Stenosis Patients Undergoing Transcatheter Aortic Valve Replacement

    by Simina Mariana Moroz, Alina Gabriela Negru, Silvia Luca, Daniel Nișulescu, Mirela Baba, Darius Buriman, Ana Lascu, Daniel Florin Lighezan, Ioana Mozos

    Aortic stenosis (AS), a progressive valvular disease that results in increasing left ventricular (LV) afterload, leads to ventricular dysfunction and heart failure if left untreated. Transcatheter aortic valve replacement (TAVR) has emerged as a minimally invasive and effective alternative to surgical replacement, especially in elderly or high-risk patients. Objectives: The present study aims to assess the influence of the tricuspid annular plane systolic excursion (TAPSE)/pulmonary systolic arterial pressure (PASP) ratio on clinical outcomes in patients with aortic stenosis undergoing TAVR and offer valuable insights into patient selection and tailored management strategies for individuals undergoing TAVR. Methods: A retrospective analysis was conducted on 100 patients with AS who underwent TAVR, included in two distinct groups based on their median TAPSE/PASP ratio. Results: Patients were divided according to their median TAPSE/PASP ratio into two groups. Those with lower TAPSE/PASP ratios had a higher incidence of post-procedural atrial fibrillation (AF) (48% vs. 28%, p = 0.0404), lower left-ventricular ejection fraction (LVEF) (41.06% vs. 49.50%, p < 0.0001), a more pronounced inflammatory and hematologic response, and longer hospitalization. Receiver-operating characteristic (ROC) analysis demonstrated modest but significant discrimination rather than high sensitivity or specificity for postprocedural arrhythmias, particularly atrial fibrillation. Conclusions: TAPSE/PASP should be regarded as a clinically useful risk-stratification marker in patients with AS undergoing TAVR, enabling the identification of high-risk patients and optimizing peri-procedural management.


  • Open Access

    Impact of Atrial Fibrillation Type on Quality of Life and Clinical Parameters in Patients with Diabetes Mellitus

    by Paul Gabriel Ciubotaru, Nilima Rajpal Kundnani, Lucretia Marin-Bancila, Daniel-Dumitru Nisulescu, Nicolae Albulescu, Abhinav Sharma, Vlad-Sabin Ivan, Roxana Buzas, Veronica Ciocan, Daniel Florin Lighezan

    Background: Atrial fibrillation (AF) is a prevalent condition with a major influence on patients’ quality of life, especially when blood glucose and heart rate are disrupted and systemic inflammation is present. Objective: This study aimed to compare Kansas City Cardiomyopathy Questionnaire (KCCQ) scores of diabetic patients by AF type and their correlations with different clinical and biological parameters. Material and methods: The retrospective study included 220 patients, from which only 200 were selected because of missing data. Patients were divided into three groups: paroxysmal AF (n = 49), persistent AF (n = 54), and permanent AF (n = 97). Demographic, clinical, and analytical data, echocardiographic parameters, heart rate, blood glucose, renal function, and inflammatory markers were compared between the three groups and their relationship with KCCQ scores. Results: The KCCQ score was significantly higher in patients with paroxysmal AF (69.50 ± 5.93), compared to persistent AF (56.92 ± 3.04) and permanent AF (42.28 ± 5.89), p < 0.001. In subanalyses, based on left ventricular ejection fraction (LVEF), the same trend was maintained, with lower KCCQ scores associated with more severe forms of AF. Significant negative correlations of the KCCQ score with blood glucose level (r = −0.2535, p = 0.0003), heart rate (r = −0.3071, p < 0.0001), and neutrophil–lymphocyte ratio (NLR) (r = −0.2395, p = 0.0006), and a positive correlation with glomerular filtration rate (GFR) (r = 0.4349, p < 0.0001) were identified. Conclusions: The type of atrial fibrillation significantly influences the quality of life assessed by the KCCQ score. Clinical and analytical parameters such as blood glucose, heart rate, systemic inflammation, and renal function significantly correlate with patients’ perception of health, indicating the importance of integrated management of AF.

  • Open Access

    Retrospective Analysis of Angiographic Radial Artery Spasm Predictors

    by Adrian Sebastian Zus, Simina Crișan, Silvia Luca, Daniel Nișulescu, Mihaela-Daniela Valcovici, Oana Pătru, Mihai-Andrei Lazăr, Cristina Văcărescu, Dan Gaiță, Constantin-Tudor Luca

    Background: Radial artery spasm remains a frequent complication during transradial coronary and peripheral angiography. Despite its impact on procedural success and patient discomfort, consistent predictors remain elusive, as does a standard definition. Objectives: This study aimed to identify independent clinical, hemodynamic, and anatomical predictors of radial artery spasm using data from a single-operator, real-world cohort of patients undergoing both elective and emergency procedures, utilizing an angiographic definition of radial artery spasm. Methods: A retrospective observational analysis was conducted on 96 patients with successful radial artery access. Radial artery spasm was objectively defined as >50% luminal narrowing on radial angiography. Patient demographics, procedural characteristics, comorbidities, and arterial parameters were analyzed. Univariate and multivariate logistic regression models were used to identify significant predictors. Results: Radial artery spasm occurred in 62.5% of patients. Univariate analysis identified lower height, weight, smaller radial artery diameter, higher pain scores, and lower diastolic blood pressure as associated with radial artery spasm. In multivariate analysis, only lower body weight (β = −0.043, p = 0.0307) and smaller radial artery diameter (β = −1.352, p = 0.0200) remained independent predictors. Age, sex, and most comorbidities, including diabetes, chronic kidney disease, and peripheral artery disease, showed no significant association. Clinically, these findings suggest that simple pre-procedural assessment of patient weight and radial artery diameter may help operators identify individuals at higher risk of radial spasm, allowing for tailored preventive strategies and potentially improving procedural comfort and success. Conclusions: Our findings suggest that low body weight and small radial artery diameter are significant independent predictors of angiographic radial artery spasm, highlighting the importance of anatomical considerations over demographic or clinical factors. Preprocedural assessment of radial artery size may enhance risk stratification and guide preventive strategies. Further multicenter validation is warranted. Incorporating routine evaluation of radial artery size and body habitus into pre-procedural assessment may help identify patients who could benefit from tailored preventive approaches—such as smaller sheath sizes, increased vasodilator use, or ultrasound-guided puncture—to optimize procedural success and patient comfort.